Prosecution Insights
Last updated: November 04, 2026

Wugen Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready

Analysis

Wugen Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The actions are distributed among 3 distinct examiners and 3 distinct art units, indicating separate examination tracks within the portfolio.

AEDER, SEAN E is the busiest examiner, with 1 pending matter. Counsel should coordinate the overall technical and claim strategy while managing each response independently, since the recorded examiner and art-unit assignments are separate.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

3
Hard (75%)
1
Medium (25%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
Multi-statute (no §101)3 (75%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
CHATTIN, AMY MARIE 1 71.4% +45.9%
AEDER, SEAN E 1 57.0% +20.0%
DUNN, LINDSAY MICHELLE 1 80.0% +0.0%
EDGINGTONGIORDANO, FRANCESCA 1 72.1% +29.6%

Hard Cases (3)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18412163 EXPANSION OF MEMORY NATURAL KILLER CELLS CHATTIN, AMY MARIE —
18484253 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF DUNN, LINDSAY MICHELLE —
18447138 POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE EDGINGTONGIORDANO, FRANCESCA —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18412163 EXPANSION OF MEMORY NATURAL KILLER CELLS CHATTIN, AMY MARIE —
18501908 GENERATION OF CD3 EXPRESSING IMMUNE CELLS FOR USE IN CONJUNCTION WITH CD3 BINDING BISPECIFIC TARGETING AGENTS AEDER, SEAN E —
18447138 POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE EDGINGTONGIORDANO, FRANCESCA —

Top Art Units

Art UnitApps
1643 2
1642 1
1644 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18412163 EXPANSION OF MEMORY NATURAL KILLER CELLS CHATTIN, AMY MARIE 1643 §102§112 Non-Final OA — Pending Jan 12, 2024
18501908 GENERATION OF CD3 EXPRESSING IMMUNE CELLS FOR USE IN CONJUNCTION WITH CD3 BINDING BISPECIFIC TARGETING AGENTS AEDER, SEAN E 1642 §103 Final Rejection — Pending Nov 03, 2023
18484253 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF DUNN, LINDSAY MICHELLE 1644 §102§103§112 Non-Final OA — Pending Oct 10, 2023
18447138 POLYPEPTIDES AND THEIR USE IN TREATMENT OF DISEASE EDGINGTONGIORDANO, FRANCESCA 1643 §102§112 Non-Final OA — Pending Aug 09, 2023

Managing Wugen Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Wugen Inc. have?

Wugen Inc. has 4 pending office actions as of November 2026, spread across 3 art units and 4 examiners.

Which USPTO examiner handles the most Wugen Inc. applications?

Amy Marie Chattin has the most, with 1 of Wugen Inc.'s pending office actions.

What technology area are Wugen Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month